Vedolizumab and anti-vedolizumab antibody
Vedolizumab and anti-vedolizumab antibody-994
Biological monitoring
Entyvio
Immunogenicity testing
Vedolizumab
Provides serum concentrations of vedolizumab and anti-vedolizumab antibodies in order to optimize treatment and facilitate clinical decision-making
Drug half-life should be taken into consideration when interpreting concentrations measured in non-trough collections.
Immediately following collection, thoroughly mix sample by gently inverting 5 times
- Allow sample to clot for a minimum of 30 minutes
- Spin within two (2) hours of sample collection
Gold serum separator (SST) tube
Heparin plasma
Lavender/Dk green:
Immediatley following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting
Red:
- Allow sample to clot
- Spin within two (2) hours of sample collection
- Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as serum
Lavender/Dk green:
- Spin within two (2) hours of sample collection
- Transfer the plasma to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as the appropriate plasma type
Refrigerated (preferred) - 14 days
Ambient - 14 days
Frozen - 14 days
Freeze/thaw cylces - stable x6
- Gross hemolysis
- Gross lipemia
Electrochemiluminescence Immunoassay (ECLIA)
An interpretive report will be provided
In the absence of anti-vedolizumab antibodies, the Vedolizumab drug level reflects the total Vedolizumab concentration. In the presence of anti-vedolizumab antibodies, the Vedolizumab concentration reflects the antibody-unbound fraction of Vedolizumab.
The presence of Vedolizumab drug, even at concentrations well above target treatment levels , does not interfere with anti-Vedolizumab antibody measurement. All positive anti-Vedolizumab antibody results are verified by a confirmatory test.
80280
Vedolizumab 86898-4
Anti-Vedolizumab Antibody 86899-2